148 related articles for article (PubMed ID: 37180106)
21. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
22. The Interplay between T Cells and Cancer: The Basis of Immunotherapy.
Chen C; Liu X; Chang CY; Wang HY; Wang RF
Genes (Basel); 2023 Apr; 14(5):. PubMed ID: 37239368
[TBL] [Abstract][Full Text] [Related]
23. Identificaiton of Novel Immunogenic Human Papillomavirus Type 16 E7-Specific Epitopes Restricted to HLA-A*33;03 for Cervical Cancer Immunotherapy.
Kim S; Chung HW; Kong HY; Lim JB
Yonsei Med J; 2017 Jan; 58(1):43-50. PubMed ID: 27873494
[TBL] [Abstract][Full Text] [Related]
24. The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy.
Dass SA; Selva Rajan R; Tye GJ; Balakrishnan V
Hum Vaccin Immunother; 2021 Sep; 17(9):2981-2994. PubMed ID: 33989511
[TBL] [Abstract][Full Text] [Related]
25. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
26. Influence of chemoradiation on the immune microenvironment of cervical cancer patients.
Herter JM; Kiljan M; Kunze S; Reinscheid M; Ibruli O; Cai J; Niu L; Heßelmann I; Trommer M; Herter-Sprie GS; Köhler C; Marnitz S
Strahlenther Onkol; 2023 Feb; 199(2):121-130. PubMed ID: 36251031
[TBL] [Abstract][Full Text] [Related]
27. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
[TBL] [Abstract][Full Text] [Related]
28. Cell surface marker-based capture of neoantigen-reactive CD8
Chatani PD; Lowery FJ; Parikh NB; Hitscherich KJ; Yossef R; Hill V; Gartner JJ; Paria B; Florentin M; Ray S; Bera A; Parkhust M; Robbins P; Krishna S; Rosenberg SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258038
[TBL] [Abstract][Full Text] [Related]
29. The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling.
Bilemjian V; Vlaming MR; Álvarez Freile J; Huls G; De Bruyn M; Bremer E
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804934
[TBL] [Abstract][Full Text] [Related]
30. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
31. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
32. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
Nelson MA; Ngamcherdtrakul W; Luoh SW; Yantasee W
Cancer Metastasis Rev; 2021 Jun; 40(2):519-536. PubMed ID: 33963482
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
Huang H; Nie CP; Liu XF; Song B; Yue JH; Xu JX; He J; Li K; Feng YL; Wan T; Zheng M; Zhang YN; Ye WJ; Li JD; Li YF; Li JY; Cao XP; Liu ZM; Zhang XS; Liu Q; Zhang X; Liu JH; Li J
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35727633
[TBL] [Abstract][Full Text] [Related]
35. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Hu Z; Xia J; Fan W; Wargo J; Yang YG
Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
[TBL] [Abstract][Full Text] [Related]
36. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
37. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer.
Daniel D; Chiu C; Giraudo E; Inoue M; Mizzen LA; Chu NR; Hanahan D
Cancer Res; 2005 Mar; 65(5):2018-25. PubMed ID: 15753402
[TBL] [Abstract][Full Text] [Related]
38. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
39. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response.
He J; Xiong X; Yang H; Li D; Liu X; Li S; Liao S; Chen S; Wen X; Yu K; Fu L; Dong X; Zhu K; Xia X; Kang T; Bian C; Li X; Liu H; Ding P; Zhang X; Liu Z; Li W; Zuo Z; Zhou P
Cell Res; 2022 Jun; 32(6):530-542. PubMed ID: 35165422
[TBL] [Abstract][Full Text] [Related]
40. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
